Pay in 4 interest-free payments of $7.45 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Similar content being viewed by others Research insights What is currently known about this topic
Appetite Suppression: The central nervous system perceives a longer sense of fullness, leading to a reduced caloric intake
Patients should follow the instructions provided with the injection pen and any guidance given by their clinician or pharmacist
Emotional eating triggers and grazing behaviors frequently resurface
Heres what it means for Medicaid enrollees: Medicaid access through the BALANCE Model could begin as early as May 2026 States must opt in voluntarily its not automatic Participating states receive federally negotiated prices from Eli Lilly (Zepbound, Mounjaro) and Novo Nordisk (Wegovy, Ozempic) Wegovy and Zepbound starting doses would cost the program $350/month (reduced from over $1,000) Patients in participating states would pay $50/month for covered GLP-1s Prior authorization and qualifying criteria will still apply This is the biggest potential expansion of GLP-1 access for Medicaid enrollees in history but it depends on your state deciding to participate
US$ 25.30
US$ 28.12
US$ 27.30
US$ 28.51
US$ 25.56
